For any drug development process, pre-clinical testing is the first step in obtaining key evidence on the tested compound’s in vivo effectiveness, providing integral-insights that influence decisions saving time and money. Therefore, it is crucial to use precision animal models that closely mimic the complexity of human pathologies. “We are supporting pharmaceutical and biotech companies across the globe to prime their drugs for success by providing custom-tailored quality pre-clinical services,” says Maria C. Denis, Chief Executive Officer at Biomedcode. An innovative contract research organization (CRO), Biomedcode, offers a diverse array of advanced pre-clinical evaluation platforms and services supported by the firm’s highly active R&D program aiming to generate and standardize novel humanized disease models to serve as preclinical tools.
Biomedcode’s highly trained and experienced personnel provides scientific consultation and method development approaches to meet the efficacy and cost-saving targets of drug development projects. “Biomedcode has the expertise, experience and tools to develop custom-tailored novel disease models and standardized methodologies” adds Niki Karagianni, Chief Scientific Officer at Biomedcode.

Biomedcode’s unique portfolio of genetic or induced mouse disease models humanized for TNF, TNFR1, RANKL, IL17A and IL23p19 closely recapitulate the pathology and complexity of human inflammatory diseases such as arthritis, spondyloarthritis, osteoporosis, psoriasis, IBD, multiple sclerosis and others.